Home
Company
Drug Development
Technology
Partnering
Investors
Imprint

Welcome to conoGenetix biosciences GmbH!

conoGenetix - located in the heart of the Biotech-Cluster Martinsried - is a privately owned biopharmaceutical company focused on the development of new peptide therapeutics for the treatment of autoimmune diseases.

conoGenetix was founded in 2002 by Dr. Andreas Klostermann and Dr. Jörg Stockhaus. The company has developed an integrated technology platform that allows for the efficient discovery of drug leads that modulate ion channel targets causatively involved in the generation of autoimmune diseases. conoGenetix runs a program targeting severe autoimmune disorders like Vasculitis, Multiple Sclerosis (MS) and Rheumatoid Arthritis (RA) having several drug candidates in preclinical development.


 

 

conoGenetix biosciences GmbH